Progentos Therapeutics, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Progentos Therapeutics, Inc - overview
Established
2024
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Founded in 2024 by co-founders Chris Loose and Sanjay Magavi and based in Massachusetts, US, Progentos Therapeutics offers research and manufactures medicines for chronic illnesses like multiple sclerosis. In May 2024, Progentos Therapeutics raised USD 65 million in Series A funding led by investor Forbion, with participation from other investors Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures. Progentos is developing small-molecule drugs that target oligodendrocyte progenitor cells, which are responsible for producing myelin and activating cells to promote myelin regeneration, potentially restoring function lost due to MS damage. The company will use the May 2024 funding to grow and broaden its MS program and pipeline of the organization.
Current Investors
Alta Partners, Forbion, Longwood Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.progentos.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.